# Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

> **NCT03207529** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Advanced Breast Carcinoma
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Androgen Receptor Positive
- HER2/Neu Negative
- Metastatic Breast Carcinoma
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- PTEN Positive
- Recurrent Breast Carcinoma
- Refractory Breast Carcinoma
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Alpelisib
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03207529
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-07
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03207529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03207529, "Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03207529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*